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Purpose: To evaluate the impact of intravitreal aﬂibercept (EYLEA, Regeneron Pharmaceuticals, Tarrytown,
NY) versus laser on progression of diabetic retinopathy (DR) severity in Intravitreal Aﬂibercept Injection in Vision
Impairment due to DME (VIVID-DME) and Study of Intravitreal Aﬂibercept Injection in Patients with Diabetic
Macular Edema (VISTA-DME).
Design: Secondary and exploratory analyses of 2 phase 3, randomized, controlled studies.
Participants: All patients with a baseline Diabetic Retinopathy Severity Scale (DRSS) score based on fundus
photograph (full analysis), patients who progressed to proliferative DR (PDR) (safety analysis) in VIVID-DME
(n ¼ 403) and VISTA-DME (n ¼ 459), or both.
Methods: We randomized patients with diabetic macular edema (DME) to intravitreal aﬂibercept 2 mg every 4
weeks (2q4), intravitreal aﬂibercept 2 mg every 8 weeks after 5 initial monthly doses (2q8), or macular laser
photocoagulation at baseline and sham injections at every visit.
Main Outcome Measures: Proportions of patients with 2-step or more and 3-step or more improvements
from baseline in DRSS score, who progressed to PDR, and who underwent panretinal photocoagulation (PRP).
Results: Among patients with an assessable baseline DRSS score, most showed moderately severe or severe
nonproliferative DR. The proportions of patients treatedwith 2q4, 2q8, and laserwith a 2-step ormore improvement in
DRSS score at week 100 were 29.3%, 32.6%, and 8.2%, respectively, in VIVID-DME and 37.0%, 37.1%, and 15.6%,
respectively, in VISTA-DME; the proportions with a 3-step or more improvement in DRSS score were 7.3%, 2.3%,
and 0%, respectively, and 22.7%, 19.9%, and 5.2%, respectively. Fewer patients in the 2q4 and 2q8 groups versus
the laser group progressed to PDR at week 100 in VISTA-DME (1.5% and 2.2% vs. 5.3%) and VIVID-DME (3.2%
and 2.0% vs. 12.3%). The proportions of patients who underwent PRP were 2.9%, 0.7%, and 4.5%, respectively,
in VIVID-DME and 1.9%, 0.7%, and 5.2%, respectively, in VISTA-DME. The most frequent serious ocular adverse
event at week 100 was cataract (pooled intravitreal aﬂibercept, 1.7% of patients; laser, 3.5% of patients).
Conclusions: These analyses demonstrate the beneﬁt of intravitreal aﬂibercept over laser with respect to DR
progression, suggesting a beneﬁt on DME, and on underlying DR. Ophthalmology Retina 2018;2:988-996 ª 2018
by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
See Editorial on page 985.
Diabetic retinopathy (DR) is a progressive dysfunction of progresses. Most vision loss associated with DR is the
the retinal vasculature resulting from chronic hyperglyce-
mia.1 Diabetic retinopathy has been classiﬁed into 4 stages:
mild nonproliferative DR (NPDR), moderate NPDR, severe
NPDR, and proliferative DR (PDR). Typical management of
mild and moderate NPDR involves observation and
improved control of diabetes, whereas severe NPDR and
PDR require referral to an ophthalmologist. Treatment
options for DR in the absence of diabetic macular edema
(DME) target only proliferative stages of DR.
Diabetic macular edema may occur at any point in the
course of DR, although it is more frequent as the disease988  2018 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Incresult of DME.2 The estimated global prevalence of
DME currently is approximately 21 million,3 and this is
expected to increase with the rising diabetes prevalence;
diabetes is projected to affect nearly 600 million people
worldwide by 2035.4
Intravitreal antievascular endothelial growth factor
(VEGF) agents (aﬂibercept [EYLEA, Regeneron Pharma-
ceuticals, Tarrytown, NY] and ranibizumab) are superior to
laser for the treatment of center-involved DME.5e9 Intra-
vitreal aﬂibercept showed similar sustainable visual acuity
(VA) gains with dosing every other month compared with.
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Institutes of Healthefunded Protocol T study conducted by
the Diabetic Retinopathy Clinical Research Network
compared intravitreal aﬂibercept, ranibizumab, and non-
licensed bevacizumab head to head.10 At 12 months, VA
gains achieved with intravitreal aﬂibercept, the study’s
primary end point, were statistically superior to those
achieved with ranibizumab or bevacizumab, particularly
in patients with baseline VA of 20/50 or worse.10 After
2 years, the visual gains achieved with intravitreal
aﬂibercept were statistically superior to those with
bevacizumab, but not ranibizumab11; however, an area
under the curve analysis showed that mean change in VA
over 2 years was greater with intravitreal aﬂibercept than
with bevacizumab or ranibizumab.12
Vascular endothelial growth factor inhibition has been
shown not only to inﬂuence the course of DME positively,
but also to have a positive impact on overall DR
severity.6,13,14 Herein we report on an unplanned retro-
spective analysis of the impact of intravitreal aﬂibercept
treatment on changes in Diabetic Retinopathy Severity Scale
(DRSS) scores, progression of DR to PDR in patients with
DME, and use of panretinal photocoagulation (PRP) in the
Intravitreal Aﬂibercept Injection in Vision Impairment due
to DME (VIVID-DME) and Study of Intravitreal Aﬂi-




Study design and methods have been published previously.8,9 Key
details are summarized here. Both VIVID-DME (clinicaltrials.gov
identiﬁer, NCT01331681) and VISTA-DME (clinicaltrials.gov
identiﬁer, NCT01363440) were phase 3, randomized, double-
masked, active-controlled, 148-week trials comparing 2 dosing
regimens of intravitreal aﬂibercept with laser for the treatment of
DME. The studies were conducted at 127 sites in the Unites States,
Europe, Japan, and Australia and in accordance with the principles
of the Declaration of Helsinki and International Conference on
Harmonisation. All information presented in this study complies
with the Health Insurance Portability and Accountability Act for
United States sites. Institutional review board or ethics committee
approval was obtained at each site before the studies commenced,
and all patients provided written consent.
Participants
Adult patients with diabetes mellitus with central DME involve-
ment (deﬁned as retinal thickening involving the 1-mm central
OCT subﬁeld [central subﬁeld thickness]) were included if best-
corrected VA (BCVA) was between 73 and 24 letters (Snellen
equivalent, 20/40e20/320) in the study eye. Only 1 eye per patient
was included.
Randomization and Treatment
We randomized patients 1:1:1 to treatment with intravitreal aﬂi-
bercept 2.0 mg every 4 weeks (2q4), intravitreal aﬂibercept 2.0 mg
every 8 weeks after 5 initial monthly doses (2q8), or macular laser
photocoagulation at baseline and sham injections at every visit.
Eyes in the 2q8 group received sham injections on nontreatmentvisits. From week 24 onward, additional active treatment (laser in
the intravitreal aﬂibercept groups or intravitreal aﬂibercept in the
laser group) was allowed if BCVA decreased because of disease
reoccurrence or worsening based on prespeciﬁed criteria. Pan-
retinal photocoagulation was allowed at any time at the in-
vestigator’s discretion for PDR.
Outcomes
The primary efﬁcacy end point in VIVID-DME and VISTA-DME
was the BCVA change from baseline in Early Treatment Diabetic
Retinopathy Study (ETDRS) letter scores at week 52. Results for
the primary end point of these studies are reported elsewhere.8
Herein, we report the proportion of eyes with 2-step or more and
3-step or more improvement in DRSS score at weeks 52 and 100,
the proportion of eyes in which PDR developed at weeks 52 and
100, and the proportion of eyes that underwent PRP at weeks 52
and 100. The 2-step or more improvement in DRSS score was a
prespeciﬁed secondary end point at week 52 and an exploratory
end point at week 100 for these studies.
We assessed central subﬁeld thickening using spectral-
domain OCT every 4 weeks, and performed ﬂuorescein angi-
ography and color fundus photography at baseline and weeks
24, 52, and 100. Masked graders evaluated images at indepen-
dent reading centers. For VIVID-DME, readers at the Vienna
Reading Center (Vienna, Austria) evaluated OCT images and
fundus images. For VISTA-DME, clinicians at the Duke
Reading Center (Durham, NC) assessed OCT images and cli-
nicians at the Digital Angiography Reading Center (Great Neck,
NY) evaluated fundus images. Although the 2 reading centers
used similar methods, the differences in the proportions of
ungradable images at baseline were the result of slightly
different algorithms used by each center.
Patients were considered to have PDR if their baseline DRSS
score was less than 61 and there was at least 1 postbaseline DRSS
score of 61 or more. Laser photocoagulation (panretinal or macu-
lar) in the study eye within 90 days of day 1 and active PDR in the
study eye were exclusion criteria for VIVID-DME and VISTA-
DME. Approximately 5% of patients demonstrated PDR at base-
line. It was agreed by the reading centers that DRSS level 60
(which indicates prior PRP) would not be used in the study,
and therefore patients with prior PRP could still improve on the
DRSS scale.
Statistical Analysis
Patients included in the efﬁcacy analyses are those from the full
analysis set (FAS) in both studies (VIVID-DME and VISTA-
DME). This includes all randomized patients who received any
study medication and underwent at least 1 baseline and 1 post-
baseline assessment. We analyzed the FAS as randomized. In
calculating the percentage of patients with a 2-step or more and
3-step or more improvement in DRSS score, the denominator for
VIVID-DME was all patients in the FAS who had a baseline
evaluable measurement of DRSS score and at least 1 postbaseline
evaluable assessment of DRSS score; the denominator for
VISTA-DME was all patients in the FAS. For patients missing a
DRSS score at weeks 52 and 100, we imputed missing values
using the last observation carried forward method, in which we
used the last value before additional treatment for eyes that
received additional treatment. The use of these different de-
nominators is consistent with the health authority submission
packages for the 2 studies. For the end point of PDR develop-
ment, we excluded missing and ungradable entries for DRSS
score from both studies.989
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(2q4, 2q8, and laser) for VIVID-DME and VISTA-DME. Addi-
tionally, given the low number of cases of incident PDR, we in-
tegrated the populations from both studies and calculated the end
points for 2 groups from that integrated population: a pooled
intravitreal aﬂibercept group (2q4 and 2q8) and laser group. In the
case of the integrated and pooled results, we based P values on the
Fisher exact test without further adjusting for multiplicities. Pa-
tients included in safety analyses are from the safety population in
both studies, which includes all randomized patients who received
any study treatment.Results
Changes from Baseline in Diabetic Retinopathy
Severity Scale Scores
Of 862 patients in the FAS, 748 (86.8%) had a baseline DRSS
score (Table 1). The proportions of DRSS images categorized as
ungradable were 25%, 28.7%, and 25.2% for the Vienna
Reading Center and 2.6%, 0.6%, and 2.0% for the Digital
Angiography Reading Center for the laser, 2q4, and 2q8 groups,
respectively.
A greater proportion of patients treated with intravitreal aﬂi-
bercept (both 2q4 and 2q8) in both VIVID-DME and VISTA-DME
demonstrated a 2-step or more improvement in DRSS scores at
weeks 52 and 100 compared with laser-treated patients (Fig 1).
When the data from the studies were integrated, the proportion
of patients who showed a 2-step or more improvement was
greater in the pooled intravitreal aﬂibercept group compared with
the laser group (week 52: 31.1% vs. 12.0%, P < 0.0001; week 100:
34.9% vs. 13.0%, P < 0.0001; n ¼ 578 and 287, respectively, for












None 10 0 0
Mild to moderate NPDR 20 1 (0.8) 0
35 2 (1.5) 0
43 36 (27.3) 31 (22.8)
Moderately
severe/severe NPDR
47 24 (18.2) 18 (13.2)
53 35 (26.5) 44 (32.4)
Mild/moderate/high-risk/
advanced PDR
61 1 (0.8) 2 (1.5)
65 0 2 (1.5)
71 0 0
75 0 0
Cannot grade 90 33 (25) 39 (28.7)
NPDR ¼ nonproliferative diabetic retinopathy; PDR ¼ proliferative diabetic
Impairment due to DME; VIVID-DME ¼ Study of Intravitreal Aﬂibercept Inje
Full analysis set. Data are no. (%).
990The proportion of patients with a 3-step or more improvement
in DRSS score at weeks 52 and 100 was greater among the groups
treated with intravitreal aﬂibercept 2q4 and 2q8 than among those
treated with laser (Fig 2). When the data from the studies were
integrated, the proportion of patients who showed a 3-step or
more improvement was greater in the pooled intravitreal aﬂibercept
group compared with the laser group (week 52: 10.7% vs. 3.4%,
P ¼ 0.0008; week 100: 15.4% vs. 3.3%, P < 0.0001; n ¼ 578 and
287, respectively, for both time points). Figure 3 shows a
representative example of a fundus photograph from a patient
treated with intravitreal aﬂibercept who experienced a 2-step or
more improvement in DRSS score at week 52.
Progression to Proliferative Diabetic
Retinopathy
A smaller proportion of patients in the intravitreal aﬂibercept 2q4
and 2q8 groups demonstrated PDR through weeks 52 and 100
compared with patients in the laser group (Fig 4). When the data
from the studies were integrated, the proportion of patients in
whom PDR developed was smaller in the pooled intravitreal
aﬂibercept group compared with the laser group (week 52: 1.7%
vs. 7.0%, P ¼ 0.0002; week 100: 2.2% vs. 9.1%, P  0.0001;
n ¼ 578 and 287, respectively, for both time points).
Finally, the proportion of patients treated with intravitreal aﬂi-
bercept 2q4 and 2q8 versus laser who received PRP through weeks
52 and 100 was smaller than the proportion of laser-treated patients
who received PRP (Fig 5). When we integrated the data from the
studies, the proportion of patients who received PRP developed
was smaller in the pooled intravitreal aﬂibercept group compared
with the laser group (week 52: 0.9% vs. 3.5%, P ¼ 0.0099;
week 100: 1.6% vs. 4.9%, P ¼ 0.0064; n ¼ 578 and 287,




















0 1 (0.6) 4 (2.6) 4 (2.6)
0 3 (1.9) 5 (3.2) 3 (2.0)
1 (0.7) 5 (3.2) 7 (4.5) 9 (6.0)
28 (20.7) 60 (39.0) 49 (31.8) 52 (34.4)
27 (20.0) 26 (16.9) 26 (16.9) 32 (21.2)
42 (31.1) 42 (27.3) 53 (34.4) 40 (26.5)
2 (1.5) 1 (0.6) 1 (0.6) 2 (1.3)
1 (0.7) 10 (6.5) 4 (2.6) 5 (3.3)
0 1 (0.6) 4 (2.6) 1 (0.7)
0 1 (0.6) 0 0
34 (25.2) 4 (2.6) 1 (0.6) 3 (2.0)
retinopathy; VISTA-DME ¼ Intravitreal Aﬂibercept Injection in Vision
ction in Patients with Diabetic Macular Edema.
Figure 1. Bar graph showing the proportion of patients with 2-step or more improvement in Diabetic Retinopathy Severity Scale (DRSS) score. For analysis
of DRSS, all patients in the full analysis set (FAS) who had a baseline evaluable measurement of DRSS score and at least 1 postbaseline evaluable assessment
of DRSS score were included. VIVID-DME: laser, n ¼ 132; 2 mg every 4 weeks (2q4), n ¼ 136; 2 mg every 8 weeks after 5 initial monthly doses (2q8),
n ¼ 135; VISTA-DME: laser, n ¼ 154; 2q4, n ¼ 154; 2q8, n ¼ 151.
Mitchell et al  DR Progression in VIVID-DME and VISTA-DMEPRP; it is possible that PRP was administered at time points other
than the DRSS reading time points, leading to the different
proportions seen in Figures 4 and 5.
Safety
The incidence of adverse events related to the progression of DR
was low. The proportions of patients who underwent vitrectomy inFigure 2. Bar graph showing the proportion of patients with 3-step or more impr
of DRSS, all patients in the full analysis set (FAS) who had a baseline evaluable m
of DRSS score were included. VIVID-DME: laser, n ¼ 132; 2 mg every 4 week
n ¼ 135; VISTA-DME: laser, n ¼ 154; 2q4, n ¼ 154; 2q8, n ¼ 151.the laser, intravitreal aﬂibercept 2q4, and intravitreal aﬂibercept
2q8 treatment groups were 0%, 0.7%, and 0%, respectively, in
VIVID-DME and 0.6%, 1.9%, and 0.7%, respectively, in VISTA-
DME. The proportions of patients in the laser, intravitreal
aﬂibercept 2q4, and intravitreal aﬂibercept 2q8 treatment groups in
whom vitreous hemorrhage developed through week 100 were
4.5%, 2.9%, and 3.0%, respectively, in VIVID-DME and 9.1%,
6.5%, and 2.0%, respectively, in VISTA-DME.ovement in Diabetic Retinopathy Severity Scale (DRSS) score. For analysis
easurement of DRSS score and at least 1 postbaseline evaluable assessment
s (2q4), n ¼ 136; 2 mg every 8 weeks after 5 initial monthly doses (2q8),
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Figure 3. Representative examples of fundus photographs from an intra-
vitreal aﬂibercept-treated patient from VIVID-DME who experienced a
2-step or more improvement in Diabetic Retinopathy Severity Scale
(DRSS) score (A) at baseline and (B) at week 52.
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These analyses evaluated the impact of intravitreal aﬂi-
bercept on DR in patients with DME enrolled in the VIVID-
DME and VISTA-DME trials. Compared with laser, the
proportion of patients in the intravitreal aﬂibercept groups
who achieved a 2-step or more and 3-step or more
improvement in DRSS score was greater, and the proportion
of patients in whom PDR developed, who were treated with
PRP, or both was smaller. These results were seen in both
the 2q4 and 2q8 treatment groups, suggesting that a reduced
number of intravitreal aﬂibercept injections does not
decrease the treatment beneﬁt provided.992The Diabetic Retinopathy Clinical Research Network
Protocol S study demonstrated that, in eyes with PDR,
ranibizumab 0.5 mg administered as needed was noninferior
to PRP with respect to BCVA outcomes at 2 years, and the
cumulative beneﬁt of ranibizumab over the study period was
superior to PRP.15 In the Clinical Efﬁcacy of Intravitreal
Aﬂibercept versus Panretinal Photocoagulation for Best
Corrected Visual Acuity in Patients with Proliferative
Diabetic Retinopathy at 52 weeks (CLARITY) study,
intravitreal aﬂibercept administered as needed (after 3
initial monthly doses) was noninferior and superior to
PRP in terms of mean change in BCVA at 52 weeks.16
The Diabetic Anti-VEGF study compared ranibizumab
0.3-mg monotherapy with combination ranibizumab plus
targeted retinal photocoagulation and found no differences
between groups in visual improvement or decreases in
central retinal thickness (Brown DM et al. Unpublished
observations, 2015). These studies suggest a beneﬁcial ef-
fect of anti-VEGF on the underlying diffuse DR in eyes with
DME, which also was seen in the current analyses.
The VIVID-DME and VISTA-DME trials were the ﬁrst
anti-VEGF studies to examine the improvement of DR as a
prespeciﬁed end point; however, progression of DR has been
evaluated in other studies. The A Study of Ranibizumab
Injection in Subjects With Clinically Signiﬁcant Macular
Edema (ME)With Center Involvement Secondary to Diabetes
Mellitus (RISE) and A Study of Ranibizumab Injection in
Subjects With Clinically Signiﬁcant Macular Edema (ME)
With Center Involvement Secondary to Diabetes Mellitus
(RIDE) studies found a trend similar to those seen in VIVID-
DME and VISTA-DME, with a greater proportion of
ranibizumab-treated patients experiencing a 2-step or more or
3-step or more improvement in DRSS score compared with
sham-treated patients and a smaller proportion in whom PDR
developed or who underwent PRP.17 However, the results in
RISE and RIDE were achieved with monthly injections of
ranibizumab (median of 24 injections over 2 years),5
whereas in the 2q8 group of VIVID-DME and VISTA-
DME, the total number of injections received from baseline
to week 100 was lower (mean, 13.5 injections in VISTA and
13.6 injections in VIVID over 2 years9). Additionally, the
distribution of baseline DRSS scores was different in RISE
and RIDE compared with VIVID-DME and VISTA-DME.
In RISE and RIDE, the distribution of patients with mild to
moderate NPDR, moderately severe to severe NPDR, and
PDR was roughly equal (approximately one third of patients
in each group).17 In VIVID-DME and VISTA-DME, nearly
half of patients demonstrated moderately severe to severe
NPDR at baseline, and less than 10% demonstrated PDR
(Table 1).
The Diabetic Retinopathy Clinical Research Network
conducted an exploratory analysis of the Protocol I study to
evaluate the effects of intravitreal ranibizumab or triamcin-
olone on the progression of DR, which was deﬁned as (1)
worsening from no PDR to PDR, (2) worsening of 2 or more
severity levels on reading center assessment of fundus
photographs in eyes without PDR at baseline, (3) having
PRP, (4) having vitreous hemorrhage, or (5) requiring vit-
rectomy for treatment of PDR. Intravitreal ranibizumab was
associated with a reduced risk of DR worsening in eyes with
Figure 4. Bar graph showing the proportion of patients in whom proliferative diabetic retinopathy (PDR) developed, safety analysis set. For both studies,
PDR development was deﬁned as patients with baseline Diabetic Retinopathy Severity Scale (DRSS) value of less than 61 and at least 1 postbaseline DRSS
value of 61 or more. VIVID-DME: laser, n ¼ 133; 2 mg every 4 weeks (2q4), n ¼ 136; 2 mg every 8 weeks after 5 initial monthly doses (2q8), n ¼ 135;
VISTA-DME: laser, n ¼ 154; 2q4, n ¼ 155; 2q8, n ¼ 152.
Mitchell et al  DR Progression in VIVID-DME and VISTA-DMEor without PDR, and intravitreal triamcinolone was associ-
ated with a reduced risk of PDR worsening.18
A post hoc analysis of the Protocol T study evaluated the
proportion of patients with DR improvement at 1 and 2
years and the cumulative probabilities for DR worsening
through 2 years without adjustment for multiple outcomes.
In eyes with NPDR at baseline, anti-VEGF treatment
resulted in improvement in DR severity for 22.1% to 37.7%Figure 5. Bar graph showing the proportion of patients who underwent panretin
mg every 4 weeks (2q4), n ¼ 136; 2 mg every 8 weeks after 5 initial monthly
n ¼ 152.at year 1 and 22.1% to 31.0% at year 2; less improvement
was observed with bevacizumab compared with intravitreal
aﬂibercept or ranibizumab. Among eyes with PDR at
baseline, intravitreal aﬂibercept was associated with more
DR improvement at 1 and 2 years. Use of all 3 anti-VEGF
agents was associated with low rates of DR worsening.14
In the ETDRS, 1 eye of each patient was assigned to
early photocoagulation, whereas the other was assigned toal laser photocoagulation, safety analysis set. VIVID-DME: laser, n ¼ 133; 2
doses (2q8), n ¼ 135; VISTA-DME: laser, n ¼ 154; 2q4, n ¼ 155; 2q8,
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natural course of DR in the initially untreated eye. The
proportions of eyes with progression to PDR were 22.8%,
40.2%, and 54.7%, at 1, 3, and 5 years of follow-up,
respectively.19 These proportions are substantially higher
than the proportions of patients in whom PDR developed,
who underwent PRP, or both in any of the treatment
groups of VIVID-DME and VISTA-DME. The lower rates
seen in the current studies may be the result of temporal
improvements in glycemic control made possible by ad-
vances in diabetes treatment over the last 25 years, shown to
reduce progression of DR.20e24 Mean baseline hemoglobin
A1c levels for patients in VIVID-DME and VISTA-DME
ranged from 7.6% to 7.9% and did not change over the
course of the study; in contrast, 42.0% of patients enrolled
in the ETDRS before 1983 had a baseline hemoglobin A1c
of 10% or more.25
The current analysis has some limitations. The relative
infrequency of DRSS measurements (at baseline, weeks 24,
52, 72 [VISTA-DME] or 76 [VIVID-DME], and 100)
means that it is possible that there are patients in any
treatment group who did progress to PDR, but that this
resolved spontaneously during continued treatment and was
not captured. Additionally, investigators administered PRP
at their discretion, a clinical decision that likely was driven
by multiple factors. There was no speciﬁc guidance indi-
cating when PRP should be performed, and therefore some
investigators may have chosen to wait for high-risk PDR to
develop. Others may have deferred PRP because of the
expectation of a positive treatment effect on the condition.
Finally, images for the 2 studies were graded by 2 different
reading centers. The reading centers used different criteria to
grade images; however, both approaches are considered
valid per the ETDRS DRSS protocol. The overall similarity
of the results between the 2 studies suggests that the
different grading criteria did not impact the outcomes.
In conclusion, these analyses through week 100
demonstrated the beneﬁts of intravitreal aﬂibercept over
laser in terms of DR progression, improvement, and out-
comes, suggesting that intravitreal aﬂibercept has a beneﬁ-
cial impact not only on localized DME, but also on the
underlying DR.
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.edu.au.Pictures & Perspectives
Laser Pointer Maculopathy
An 11-year old Caucasian boy was referred for loss of vision for 1 year concerning for inherited retinal dystrophy. Best-corrected visual
acuity was 20/30 in the right eye and 20/80 in the left. No family history of early vision loss was noted. Anterior segment examination was
unremarkable. Dilated fundus examination showed irregular areas of foveal atrophy in both eyes. OCT shows a focal, well-circumscribed
area of photoreceptor loss subfoveally in the left eye and parafoveally in the right eye. Upon further questioning, he admits that before
noticing the vision changes a friend had shined a laser pointer in his eyes for a prolonged period of time.
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